Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Endocrinology
•
HIV & AIDS
•
Primary Care
What patient-specific factors would influence your decision to initiate semaglutide therapy in patients with HIV-associated lipohypertrophy?
Answer from: at Academic Institution
I would consider it if the patient had diabetes. But there is not much data on this question.
Comments
at George Washington School Of Medicine
Is there any data?
13807
Sign in or Register to read more
25057
Related Questions
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
How do you use CD4% in clinical practice in management of patients living with HIV?
How long would you hold clomiphene before checking baseline morning testosterone levels to evaluate the need for testosterone replacement therapy initiation?
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How do you approach treatment of depression in Graves' Disease?
How do you counsel patients on the likelihood of resolution of their hypertension post adrenalectomy for primary hyperaldosteronism?
Do you recommend a trial of testosterone replacement therapy in male patients with symptoms consistent with hypogonadism, low total testosterone but normal free androgen index (FAI)?
Is there any data?